Get the Stockscreener App
2.225
14.09%
-0.365
After Hours:
2.28
0.055
+2.47%
Abvc Biopharma Inc stock is traded at $2.225, with a volume of 953.84K.
It is down -14.09% in the last 24 hours and up +62.41% over the past month.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
See More
Previous Close:
$2.59
Open:
$2.65
24h Volume:
953.84K
Relative Volume:
2.50
Market Cap:
$28.19M
Revenue:
$152.40K
Net Income/Loss:
$-10.52M
P/E Ratio:
-0.8925
EPS:
-2.4931
Net Cash Flow:
$-4.26M
1W Performance:
+13.52%
1M Performance:
+62.41%
6M Performance:
+277.12%
1Y Performance:
+187.47%
1-Day Range:
$2.16
$2.70
1-Week Range:
$1.96
$2.70
52-Week Range:
$0.40
$2.70
Abvc Biopharma Inc Stock (ABVC) Company Profile
Name
Abvc Biopharma Inc
Sector
Industry
Phone
510-668-0881
Address
44370 OLD WARM SPRINGS BLVD., FREMONT
Compare ABVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVC
Abvc Biopharma Inc
|
2.225 | 28.19M | 152.40K | -10.52M | -4.26M | -2.4931 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Abvc Biopharma Inc Stock (ABVC) Latest News
ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform to Strengthen Oncology Portfolio - citybuzz -
ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million - The Globe and Mail
ABVC BioPharma Shareholders Approve Key Proposals - TipRanks
ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value - Yahoo Finance
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Up 40.0% in May - Defense World
3 Top Growth Stocks to Buy in the Second Half of 2025 - The Globe and Mail
ABVC BioPharma Files $100 Million Mixed Shelf - marketscreener.com
ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance - Yahoo Finance
ABVC BioPharma Secures Japanese Patent for Botanical Depression Treatment - citybuzz -
ABVC BioPharma Secures Japanese Patent for Its Natural MDD Treatment Candidate ABV-1504 - Yahoo Finance
ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan - Yahoo Finance
ABVC BIOPHARMA, INC. SEC 10-Q Report - TradingView
ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
UPDATE: ABVC BioPharma Announces 2024 Financial Results - Yahoo Finance
ABVC BioPharma Reports Strong Financial Growth - TipRanks
ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements - marketscreener.com
ABVC BioPharma Announces 2024 Financial Results - Yahoo Finance
ABVC BIOPHARMA, INC. SEC 10-K Report - TradingView
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
ABVC Subsidiary Acquires Taiwanese Land to Secure Botanical Drug Production - citybuzz -
ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million - Yahoo Finance
How analysts predict ABVC BioPharma Inc (ABVC) will perform this quarter? - uspostnews.com
ABVC BioPharma Delays Yearly Report Filing - TipRanks
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 22.7% in March - Defense World
ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential - Yahoo Finance
ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Significant Growth in Short Interest - The AM Reporter
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Update - Defense World
ABVC BioPharma announces CFO resignation, CEO steps in as interim By Investing.com - Investing.com Canada
ABVC BioPharma announces CFO resignation, CEO steps in as interim - Investing.com India
ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma - Marketscreener.com
ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs - Financial Content
ABVC BioPharma's CEO Discusses New Drug Development and AI Integration - ACCESS Newswire
ABVC and BioLite Japan Forge Strategic Alliance to Boost Japanese Biotech Global Expansion - citybuzz -
ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global Markets - Financial Content
ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025 - Yahoo Finance
Attention Deficit Hyperactivity Disorder Treatment Market - openPR.com
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion - Yahoo Finance
ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Decline in Short Interest - Defense World
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 42.6% in December - Defense World
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market - Yahoo Finance
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees - Yahoo Finance
Head to Head Review: ABVC BioPharma (NASDAQ:ABVC) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement - Yahoo Finance
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products - Yahoo Finance
ABVC BioPharma Expands Global Patent Portfolio for ADHD Treatment - Citybuzz
ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market - Yahoo Finance
Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Rises By 148.2% - Defense World
Abvc Biopharma Inc Stock (ABVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):